Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company?s lead product candidate, ADS-5102, is being developed for a complication of Parkinson?s disease, known as levodopa-induced dyskinesia, and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. Its portfolio also includes an NDA-submitted fixed-dose combination product candidate, MDX-8704, which is being co-developed with Forest Laboratories, Inc.; and an approved controlled-release product, Namenda XR. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
|Shares Outstanding||EPS||-2.84||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-99.1%||Sales Growth - Q/Q||-99.25%||P/E||-6.16|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||2.99%||ROE||3.2%||ROI|
|Current Ratio||14.25||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||21.43%||Net Profit Margin||7.87%||Dividend Payout Ratio|
|Cash From Financing Activities||300 K||Cash From Investing Activities||-18.45 M||Cash From Operating Activities||-14.06 M||Gross Profit|
|Net Profit||-12.2 M||Operating Profit||-12.23 M||Total Assets||147.34 M||Total Current Assets||115.52 M|
|Total Current Liabilities||8.11 M||Total Debt||Total Liabilities||9.79 M||Total Revenue||230 K|
|High 52 week||42.65||Low 52 week||5.48||Last close||5.73||Last change||-3.86%|
|RSI||31.77||Average true range||0.3||Beta||1.57||Volume||92.31 K|
|Simple moving average 20 days||-5.84%||Simple moving average 50 days||-15.11%||Simple moving average 200 days||-74%|
|Performance Week||2.32%||Performance Month||-10.47%||Performance Quart||-76.34%||Performance Half||-81.62%|
|Performance Year||-79.54%||Performance Year-to-date||-75.52%||Volatility daily||2.42%||Volatility weekly||5.41%|
|Volatility monthly||11.1%||Volatility yearly||38.44%||Relative Volume||208.74%||Average Volume||562.75 K|
|New High||New Low|
2020-06-04 16:30:10 | Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes
2020-06-03 16:01:10 | Adamas to Present at Upcoming William Blair Conference
2020-05-08 18:46:23 | Adamas Announces New Employment Inducement Grant
2020-05-08 04:11:44 | Edited Transcript of ADMS earnings conference call or presentation 7-May-20 9:00pm GMT
2020-05-07 16:03:10 | Adamas Reports First Quarter 2020 Financial Results
2020-04-28 12:00:04 | All You Need to Know About Adamas ADMS Rating Upgrade to Buy
2020-04-10 16:06:10 | Adamas Announces New Employment Inducement Grant
2020-03-23 15:15:56 | Adamas Pharmaceuticals Stock – Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors – ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.
2020-03-20 10:44:02 | Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
2020-03-19 16:46:00 | Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.
2020-03-07 09:56:26 | Edited Transcript of ADMS earnings conference call or presentation 25-Feb-20 9:30pm GMT
2020-03-06 16:39:18 | Adamas Announces New Employment Inducement Grant
2020-02-25 17:35:10 | Adamas Pharmaceuticals ADMS Reports Q4 Loss, Tops Revenue Estimates
2020-02-25 16:03:10 | Adamas Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-24 09:02:02 | Cronos CRON to Report Q4 Earnings: What's in the Cards?
2020-02-20 16:01:10 | Adamas to Present at Upcoming Healthcare Conferences
2020-02-05 15:15:00 | 5-Day Deadline Alert: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2020-02-05 11:26:10 | ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm
2020-02-04 20:05:00 | 6-Day Deadline Alert: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2020-02-03 13:45:00 | NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm